Return to News
Argos Therapeutics Appoints Dr. John Bonfiglio Chief Executive Officer
Durham, NC- December 21, 2006 - Argos Therapeutics today announced that John N. Bonfiglio, Ph.D., will be joining the Company as President and Chief Executive Officer and as a member of the Board of Directors. Dr. Bonfiglio was most recently President and CEO of Immune Response Corporation, where he led that company´s business development strategy and oversaw multiple clinical trials, manufacturing and the development of biologic immuno-stimulatory therapeutic agents.
“Dr. Bonfiglio´s specific leadership experience in immunotherapeutic development will be a tremendous asset to Argos as our pipeline of RNA-loaded dendritic cell based immunotherapies advances,” said Hubert Birner, Ph.D., Chairman of the Board of Directors of Argos and a General Partner of TVM Capital. “His strategic vision has made a significant impact at several companies, and his proven track record in successfully managing trials, negotiating lucrative business development opportunities, and securing and managing financial resources will contribute to our growth.”
“Argos´ unique and promising approach to immunotherapy, which utilizes each patient´s own dendritic cells to trigger a patient-specific immune response, positions it well to produce important new therapies for cancer, HIV, and other infectious diseases,” commented Dr. Bonfiglio. “With a rapidly expanding clinical development pipeline, Argos is already in a strong position and I look forward to leading the Company in its mission to deliver on the promise of autologous immunotherapies.”
Prior to joining Immune Response, Dr. Bonfiglio served as Chief Operating Officer and Executive Vice President of Cypress Bioscience, where his responsibilities included business development, marketing, research and development, clinical development, strategic direction, and budgeting. He also served as President and CEO of Peregrine Pharmaceuticals, as Director of the Strategic Business Unit at Baxter Healthcare Corporation, and as Director of Business Planning at Allergan, after holding several positions of increasing responsibility over an 11-year period.
Dr. Bonfiglio holds an MBA from Pepperdine University and received his Ph.D. and Masters in Organic Chemistry from University of California — San Diego. He received a Bachelors degree in Chemistry from the State University of New York — Stony Brook.
About Argos Therapeutics, Inc.
Argos Therapeutics is developing breakthrough immunotherapies that target the unique features of a patient´s disease. This new generation of personalized cancer and HIV therapeutics trains the immune system to recognize and attack the disease. Argos´ scientific leadership in RNA-loaded dendritic cells and advanced manufacturing processes provide a platform to tackle virtually all forms of cancers and infectious diseases. www.argostherapeutics.com
Argos is a private biotechnology company headquartered in Research Triangle Park, NC. The company has multiple clinical trial programs in renal cell carcinoma (RCC), chronic lymphocytic leukemia (CLL), and human immunodeficiency virus (HIV) and has an ongoing co-development and commercialization alliance with the pharmaceutical division of Kirin Brewery Company, Limited.
MacDougall Biomedical Communications
print friendly version
# # #